Brown J E, Kitchell B B, Bjornsson T D, Shand D G
Clin Pharmacol Ther. 1981 Nov;30(5):636-43. doi: 10.1038/clpt.1981.215.
Our purpose was to determine whether the reported alteration of protein drug binding after heparin administration in man was artifactual as a result of continued in vitro activity of triglyceride lipases. The lipoprotein lipase inhibitors protamine (14 mg/ml) and ethylenediaminetetraacetic acid (10 mg/ml) were added to blood samples from 11 healthy subjects before and 15 min after 100 USP units of intravenous heparin. Heparin elevated total nonesterified fatty acid (NEFA) concentration (P less than 0.001) and free fractions of lidocaine, diazepam, and propranolol (P less than 0.001 for all). The presence of the lipase inhibitors diminished the heparin-induced elevation of NEFA (P less than 0.001) and free fractions of lidocaine (P less than 0.001) and diazepam (P less than 0.001), but these values were still greater than control. The inhibitors reduced propranolol binding in control samples and did not diminish the effects of heparin. The change in NEFA concentrations correlated with the free fraction changes of all three ligands (r = 0.739 to 0.849). These data suggest that the heparin-induced protein binding changes are to, a large extent, in vitro artifacts.
我们的目的是确定在人体中给予肝素后所报道的蛋白质药物结合变化是否是由于甘油三酯脂肪酶的持续体外活性而导致的人为现象。在100美国药典单位静脉注射肝素之前和之后15分钟,将脂蛋白脂肪酶抑制剂鱼精蛋白(14毫克/毫升)和乙二胺四乙酸(10毫克/毫升)添加到11名健康受试者的血样中。肝素使总非酯化脂肪酸(NEFA)浓度升高(P小于0.001),并使利多卡因、地西泮和普萘洛尔的游离分数升高(所有P均小于0.001)。脂肪酶抑制剂的存在减弱了肝素诱导的NEFA升高(P小于0.001)以及利多卡因(P小于0.001)和地西泮(P小于0.001)的游离分数升高,但这些值仍高于对照。抑制剂降低了对照样品中普萘洛尔的结合,并且没有减弱肝素的作用。NEFA浓度的变化与所有三种配体的游离分数变化相关(r = 0.739至0.849)。这些数据表明,肝素诱导的蛋白质结合变化在很大程度上是体外人为现象。